Arvinas Holding Company LLC(ARVN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ARVN Arvinas Holding Company LLC

Market Closed 04-17 16:00:00 EDT

8.60

+0.95

+12.42%

盘后8.62

+0.02+0.23%

19:56 EDT

High8.64	Low7.61	Vol3.19M
Open7.74	D1 Closing7.65	Amplitude13.53%
Mkt Cap591.44M	Tradable Cap461.69M	Total Shares68.77M
T/O26.35M	T/O Rate5.94%	Tradable Shares53.69M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"ARVN","market":"US","secType":"STK","nameCN":"Arvinas Holding Company LLC","latestPrice":8.6,"timestamp":1744920000000,"preClose":7.65,"halted":0,"volume":3187258,"hourTrading":{"tag":"盘后","latestPrice":8.62,"preClose":8.6,"latestTime":"19:56 EDT","volume":40402,"amount":347695.059,"timestamp":1744934172176},"delay":0,"floatShares":53685100,"shares":68771867,"eps":-2.766342,"marketStatus":"Market Closed","change":0.95,"latestTime":"04-17 16:00:00 EDT","open":7.74,"high":8.6402,"low":7.605,"amount":26352826.037698,"amplitude":0.13532,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.766342,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1745222400000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1538020800000,"exchange":"NASDAQ","adjPreClose":7.65,"preHourTrading":{"tag":"盘前","latestPrice":7.67,"preClose":7.65,"latestTime":"09:29 EDT","volume":804,"amount":6137.976396,"timestamp":1744896599999},"postHourTrading":{"tag":"盘后","latestPrice":8.62,"preClose":8.6,"latestTime":"19:56 EDT","volume":40402,"amount":347695.059,"timestamp":1744934172176},"volumeRatio":1.2530314716400703,"impliedVol":0.8649,"impliedVolPercentile":0.5737},"requestUrl":"/m/hq/s/ARVN","defaultTab":"news","newsList":[{"id":"2528216217","title":"Arvinas Is Maintained at Neutral by Goldman Sachs","url":"https://stock-news.laohu8.com/highlight/detail?id=2528216217","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528216217?lang=en_us&edition=full_marsco","pubTime":"2025-04-18 01:41","pubTimestamp":1744911660,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ARVN/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 17, 2025 13:41 ET (17:41 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARVN"],"gpt_icon":0},{"id":"2526765367","title":"Arvinas, Inc. (ARVN): Among Stocks Under $10 that Will Triple","url":"https://stock-news.laohu8.com/highlight/detail?id=2526765367","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526765367?lang=en_us&edition=full_marsco","pubTime":"2025-04-09 21:43","pubTimestamp":1744206211,"startTime":"0","endTime":"0","summary":"We recently published a list of 10 Stocks Under $10 that Will Triple. In this article, we are going to take a look at where Arvinas, Inc.  stands against other stocks under $10 that will triple.As we delve into the discussion on stocks that will triple, we must shed light on the U.S. small-cap stocks, which are struggling amid broader market challenges due to ongoing shifts in tariff policy, affecting investors’ confidence. The Russell index  has fallen over 15% from its peak in November 2024 as of the time of writing this article and is down by nearly 19% on a YTD basis. However, the broader market, mostly consisting of large-cap stocks, has only dropped about 14% on a YTD basis. This gap shows how economic uncertainties and higher interest rates have more impact on smaller companies as they typically carry more debt and feel borrowing costs more acutely.Moreover, industry changes and technological advances offer more opportunities to small-cap companies. While the AI boom has mostly ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/arvinas-inc-arvn-among-stocks-134331532.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","QID","USJW.SI","NVIW.SI","MNQmain","NQmain","USAW.SI","TQQQ","ARVN","SQQQ","QLD",".IXIC","PSQ","TSYW.SI"],"gpt_icon":1},{"id":"2526364786","title":"Arvinas Is Maintained at Buy by Truist Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2526364786","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526364786?lang=en_us&edition=full_marsco","pubTime":"2025-04-09 21:32","pubTimestamp":1744205520,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ARVN/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 09, 2025 09:32 ET (13:32 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARVN"],"gpt_icon":0},{"id":"2526357047","title":"Truist Slashes Price Target on Arvinas to $21 From $65, Keeps Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2526357047","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526357047?lang=en_us&edition=full_marsco","pubTime":"2025-04-09 19:32","pubTimestamp":1744198374,"startTime":"0","endTime":"0","summary":"Arvinas (ARVN) has an average rating of overweight and mean price target of $38.06, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major bank","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ARVN"],"gpt_icon":0},{"id":"2525022626","title":"BUZZ-Arvinas hits all-time low following Piper Sandler PT cut","url":"https://stock-news.laohu8.com/highlight/detail?id=2525022626","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525022626?lang=en_us&edition=full_marsco","pubTime":"2025-04-08 01:20","pubTimestamp":1744046421,"startTime":"0","endTime":"0","summary":"BUZZ-Arvinas hits all-time low following Piper Sandler PT cut** Shares of drug developer Arvinas ARVN.O fall 5.6% to $6.19, hitting all-time low** Piper Sandler reduces price target to $24 from $67 on narrowed Vepdegestrant ESR1-mutant mBC approval; remains \"overweight\"** Vepdegestrant, ARVN and Pfizer's PFE.N oral drug, failed to delay progression of breast cancer in patients with most common type of the disease in a late-stage trial last month** Vepdegestrant only helped to extend progression-free survival in a subgroup of participants with a specific gene mutation, the company said in March** ARVN is developing PROteolysis TArgeting Chimeras , which is a technique for the selective degradation of target proteins** PROTACs are novel technology never tested in man that may fail in the clinic; ARVN's partnerships may falter and it may require additional capital - Piper Sandler** Up to last close, stock had fallen nearly 66% YTD  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250407:nL3N3QL1JF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0122379950.USD","BK4592","LU0306806265.USD","LU1066051498.USD","SG9999002224.SGD","LU0289739699.SGD","LU0456855351.SGD","IE00BLSP4452.SGD","SG9999011175.SGD","LU0321505868.SGD","SG9999002232.USD","SG9999013999.USD","LU1894683264.USD","BK4534","ARVN","IE00BBT3K403.USD","LU0321505439.SGD","LU0225284248.USD","LU1023059063.AUD","BK4568","BK4581","SGXZ57979304.SGD","LU0225771236.USD","LU0306807586.USD","IE0002270589.USD","BK4533","BK4127","LU1883839398.USD","SG9999001176.SGD","IE00B19Z3B42.SGD","PIPR","LU0868494617.USD","BK4007","IE000M9KFDE8.USD","BK4588","IE00B19Z3581.USD","LU0058720904.USD","LU1066053197.SGD","LU1894683348.USD","LU1057294990.SGD","SG9999003800.SGD","LU0985481810.HKD","BK4585","BK4599","LU0234572021.USD","SG9999001176.USD","LU0170899867.USD","IE00BLSP4239.USD","BK4550"],"gpt_icon":1},{"id":"2525043661","title":"Arvinas Price Target Maintained With a $81.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2525043661","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525043661?lang=en_us&edition=full_marsco","pubTime":"2025-04-07 21:00","pubTimestamp":1744030800,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ARVN/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 07, 2025 09:00 ET (13:00 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARVN"],"gpt_icon":0},{"id":"2525801400","title":"Guggenheim Keeps Their Buy Rating on Arvinas Holding Company (ARVN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2525801400","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525801400?lang=en_us&edition=full_marsco","pubTime":"2025-04-07 19:36","pubTimestamp":1744025766,"startTime":"0","endTime":"0","summary":"In a report released today, Michael Schmidt from Guggenheim maintained a Buy rating on Arvinas Holding Company (ARVN – Research Report), with a pri...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/guggenheim-keeps-their-buy-rating-on-arvinas-holding-company-arvn?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/guggenheim-keeps-their-buy-rating-on-arvinas-holding-company-arvn?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ARVN"],"gpt_icon":0},{"id":"2525064358","title":"U.S. RESEARCH ROUNDUP-Apple, Tesla, Walmart","url":"https://stock-news.laohu8.com/highlight/detail?id=2525064358","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525064358?lang=en_us&edition=full_marsco","pubTime":"2025-04-07 15:22","pubTimestamp":1744010543,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Apple, Tesla, WalmartApril 7 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies including Apple, Tesla and Walma","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250407:nL3N3QL0PU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0784384876.USD","LU1169589451.USD","BK4512","LU1206713676.USD","BK4548","LU1116320901.HKD","LU1582987324.SGD","LU1934455863.HKD","AR","ARVN","PENG","TW","EQT","LU0642271901.SGD","LU2168564065.EUR","IE0004445239.USD","LU2237443895.HKD","LU1496350502.SGD","TSLA","EGP","TRNO","LU0612318385.USD","IE00BBT3K403.USD","GPOR","LU1585245621.USD","LU0724617625.USD","CATX","LU0444971666.USD","LU0553294199.USD","MACW.SI","LU2360107168.USD","SMG","TSYW.SI","AAPL","SG9999002224.SGD","RRC","CTVA","LU1035773651.USD","STZ","LU1316542783.SGD","LU0868494708.USD","SG9999014542.SGD","LU2065169927.USD","WMT","LU0788108743.HKD","BK4535","LU1430594728.SGD","LSEG.UK","LU0345781412.USD","IE00BJTD4V19.USD"],"gpt_icon":1},{"id":"2525105747","title":"Arvinas Inc : Piper Sandler Cuts Target Price to $24 From $67","url":"https://stock-news.laohu8.com/highlight/detail?id=2525105747","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525105747?lang=en_us&edition=full_marsco","pubTime":"2025-04-07 13:13","pubTimestamp":1744002832,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250407:nFWN3QI1WN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","ARVN"],"gpt_icon":0},{"id":"2525329377","title":"Arvinas Potential Parkinson's Treatment Shows Positive Data In Human Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2525329377","media":"Benzinga","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525329377?lang=en_us&edition=full_marsco","pubTime":"2025-04-05 03:38","pubTimestamp":1743795511,"startTime":"0","endTime":"0","summary":"Arvinas, Inc. unveiled first-in-human data on Friday for its experimental Parkinson’s disease treatment, ARV-102.Results from the randomized, double-blind, placebo-controlled single ascending dose  cohort of the Phase 1 healthy volunteer trial and initial results from the multiple ascending dose  cohort were shared in a presentation at the 2025 International Conference on Alzheimer’s and Parkinson’s Diseases.The Phase 1 trial included SAD cohorts from 10 mg to 200 mg and MAD cohorts of 10 mg to 80 mg in healthy volunteers.In the trial ARV-102, the company’s investigational PROteolysis TArgeting Chimera  leucine-rich repeat kinase 2  degrader, demonstrated substantial reduction of LRRK2, a multifunctional protein that has been implicated in Parkinson’s disease and progressive supranuclear palsy , in cerebral spinal fluid .Also Read: Arvinas, Pfizer Breast Cancer Drug Fails To Show Progression-Free Survival Benefit In Trial. While LRRK2 is primarily known for its role in Parkinson’s, Arv","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/arvinas-potential-parkinsons-treatment-shows-193831011.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ARVN","PSP","BK4007","CSF"],"gpt_icon":0},{"id":"2524205150","title":"Arvinas Says First-in-Human Data for ARV-102 Shows Substantial Reduction of LRRK2","url":"https://stock-news.laohu8.com/highlight/detail?id=2524205150","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524205150?lang=en_us&edition=full_marsco","pubTime":"2025-04-04 19:56","pubTimestamp":1743767815,"startTime":"0","endTime":"0","summary":"Arvinas  said Friday that data from the first-in-human clinical trial of ARV-102 demonstrated substantial reduction of leucine-rich repeat kinase 2, or LRRK2, a multifunctional protein that has been primarily implicated in Parkinson's disease.ARV-102 was generally safe and well tolerated with no serious adverse events reported after single or multiple doses, the company said.At a single oral dose of at least 60 mg, and once daily repeated oral doses of at least 20 mg, ARV-102 achieved greater than 50% LRRK2 reduction in the cerebral spinal fluid and greater than 90% LRRK2 reduction in the peripheral blood mononuclear cells.The company said its findings support continued evaluation of ARV-102 in neurodegenerative diseases associated with LRRK2 dysfunction and a phase 1 trial in patients with Parkinson's disease has been initiated and is currently enrolling.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","ARVN"],"gpt_icon":0},{"id":"2524208018","title":"Arvinas presents first-in-human data from ARV-102 trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2524208018","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524208018?lang=en_us&edition=full_marsco","pubTime":"2025-04-04 19:10","pubTimestamp":1743765045,"startTime":"0","endTime":"0","summary":"Arvinas (ARVN) presented data from the first-in-human clinical trial of ARV-102, the Company’s investigational PROteolysis TArgeting Chimera leucin...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/arvinas-presents-first-in-human-data-from-arv-102-trial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/arvinas-presents-first-in-human-data-from-arv-102-trial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","ARVN"],"gpt_icon":0},{"id":"2524332208","title":"Arvinas Inc -Data Demonstrate That Arv-102 Was Well Tolerated","url":"https://stock-news.laohu8.com/highlight/detail?id=2524332208","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524332208?lang=en_us&edition=full_marsco","pubTime":"2025-04-04 19:00","pubTimestamp":1743764430,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250404:nFWN3QI01O:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","ARVN"],"gpt_icon":0},{"id":"2524208336","title":"Arvinas Inc -Arv-102 Achieved Central and Peripheral Lrrk2 Reduction Indicating Substantial Lrrk2 Protein Degradation in Healthy Volunteers","url":"https://stock-news.laohu8.com/highlight/detail?id=2524208336","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524208336?lang=en_us&edition=full_marsco","pubTime":"2025-04-04 19:00","pubTimestamp":1743764430,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250404:nFWN3QI01O:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ARVN","BK4007"],"gpt_icon":0},{"id":"2524208330","title":"Arvinas Presents First-in-Human Data for Investigational Oral Protac Arv-102 Demonstrating Blood-Brain Barrier Penetration, and Central and Peripheral Lrrk2 Degradation","url":"https://stock-news.laohu8.com/highlight/detail?id=2524208330","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524208330?lang=en_us&edition=full_marsco","pubTime":"2025-04-04 19:00","pubTimestamp":1743764430,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250404:nFWN3QI01O:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","ARVN"],"gpt_icon":0},{"id":"2524083482","title":"Arvinas-Expects to Complete Enrollment and Present Initial Data From Ongoing Sad Cohort of Phase 1 Clinical Trial in Patients With Pd in 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2524083482","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524083482?lang=en_us&edition=full_marsco","pubTime":"2025-04-04 19:00","pubTimestamp":1743764430,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250404:nFWN3QI01O:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ARVN","BK4007"],"gpt_icon":0},{"id":"2524598262","title":"We Think Arvinas (NASDAQ:ARVN) Can Afford To Drive Business Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2524598262","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524598262?lang=en_us&edition=full_marsco","pubTime":"2025-04-03 19:52","pubTimestamp":1743681168,"startTime":"0","endTime":"0","summary":"Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the right price. For example, although Amazon.com made losses for many years after listing, if you had bought and held the shares since 1999, you would have made a fortune. But while the successes are well known, investors should not ignore the very many unprofitable companies that simply burn through all their cash and collapse.So should Arvinas  shareholders be worried about its cash burn?In this article, we define cash burn as its annual  free cash flow, which is the amount of money a company spends each year to fund its growth. Let's start with an examination of the business' cash, relative to its cash burn.This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality.Since it has a market capitalisation of US$483m, Arvinas' US$261m in cash burn equates to about 54% of its market value. That's high expenditure relative t","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/think-arvinas-nasdaq-arvn-afford-115248827.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["TSYW.SI","QID","NDAQ","LU2095319765.USD","BK4588","IE00B64PRP62.GBP","PSQ","MNQmain",".IXIC","IE00B3QW5Z07.USD","QQQ","USJW.SI","BK4585","SQQQ","TQQQ","USAW.SI","IE00BKPKM429.USD","QLD","BK4007","IE00BGHQF748.EUR","LU2210149790.SGD","ARVN","NVIW.SI","NQmain","BK4112","LU2210150020.SGD"],"gpt_icon":0},{"id":"2522375533","title":"Arvinas Announces Oral Presentation at 2025 International Conference on  Alzheimer’s & Parkinson’s Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2522375533","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522375533?lang=en_us&edition=full_marsco","pubTime":"2025-03-27 19:00","pubTimestamp":1743073224,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250327:nTUAGWDT6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","ARVN"],"gpt_icon":0},{"id":"2522759013","title":"Arvinas Announces Oral Presentation at 2025 International Conference on  Alzheimer’s & Parkinson’s Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2522759013","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522759013?lang=en_us&edition=full_marsco","pubTime":"2025-03-27 19:00","pubTimestamp":1743073200,"startTime":"0","endTime":"0","summary":"– Company to highlight first-in-human data from healthy volunteers in both the single-ascending and multiple-ascending dose portions of a Phase 1 study of ARV-102, an investigational PROTAC LRRK2 degrader –。NEW HAVEN, Conn., March 27, 2025  -- Arvinas, Inc. , a clinical-stage biotechnology company working to develop a new class of drugs based on targeted protein degradation, today announced that data from the first-in-human study evaluating single-ascending and multiple-ascending doses in healthy volunteers of ARV-102 will be presented at the International Conference on Alzheimer’s and Parkinson’s Diseases , April 1-5, 2025 in Vienna, Austria.ARV-102 is Arvinas’ investigational PROteolysis TArgeting Chimera  degrader targeting leucine-rich repeat kinase 2 , a multifunctional protein that has been implicated in Parkinson’s disease and progressive supranuclear palsy.Session Title: First-In-Human Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of ARV-102, a PROTAC LRRK2","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/arvinas-announces-oral-presentation-2025-110000880.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","ARVN"],"gpt_icon":0},{"id":"2522303387","title":"Analysts Offer Insights on Healthcare Companies: Arvinas Holding Company (ARVN), Eledon Pharmaceuticals (ELDN) and Arcutis Biotherapeutics (ARQT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2522303387","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522303387?lang=en_us&edition=full_marsco","pubTime":"2025-03-25 08:30","pubTimestamp":1742862623,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Arvinas Holding Company (ARVN – Research Report), El...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-arvinas-holding-company-arvn-eledon-pharmaceuticals-eldn-and-arcutis-biotherapeutics-arqt?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-arvinas-holding-company-arvn-eledon-pharmaceuticals-eldn-and-arcutis-biotherapeutics-arqt?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4137","BK4139","ARVN","ARQT","HCSG","BK4007","ELDN"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.arvinas.com","stockEarnings":[{"period":"1week","weight":0.2991},{"period":"1month","weight":0.0214},{"period":"3month","weight":-0.5235},{"period":"6month","weight":-0.6828},{"period":"1year","weight":-0.7429},{"period":"ytd","weight":-0.5514}],"compareEarnings":[{"period":"1week","weight":0.0035},{"period":"1month","weight":-0.0617},{"period":"3month","weight":-0.1191},{"period":"6month","weight":-0.0995},{"period":"1year","weight":0.0517},{"period":"ytd","weight":-0.1018}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.","yearOnYearQuotes":[{"month":1,"riseRate":0.428571,"avgChangeRate":0.025374},{"month":2,"riseRate":0.571429,"avgChangeRate":0.011057},{"month":3,"riseRate":0.142857,"avgChangeRate":-0.187738},{"month":4,"riseRate":0.571429,"avgChangeRate":0.075786},{"month":5,"riseRate":0.5,"avgChangeRate":-0.112391},{"month":6,"riseRate":0.833333,"avgChangeRate":0.011275},{"month":7,"riseRate":0.666667,"avgChangeRate":0.126111},{"month":8,"riseRate":0.166667,"avgChangeRate":-0.076544},{"month":9,"riseRate":0.166667,"avgChangeRate":-0.103315},{"month":10,"riseRate":0.428571,"avgChangeRate":-0.018156},{"month":11,"riseRate":0.714286,"avgChangeRate":0.161248},{"month":12,"riseRate":0.571429,"avgChangeRate":0.407187}],"exchange":"NASDAQ","name":"Arvinas Holding Company LLC","nameEN":"Arvinas Holding Company LLC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.33.2","shortVersion":"4.33.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Arvinas Holding Company LLC(ARVN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Arvinas Holding Company LLC(ARVN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Arvinas Holding Company LLC,ARVN,Arvinas Holding Company LLC股票,Arvinas Holding Company LLC股票老虎,Arvinas Holding Company LLC股票老虎国际,Arvinas Holding Company LLC行情,Arvinas Holding Company LLC股票行情,Arvinas Holding Company LLC股价,Arvinas Holding Company LLC股市,Arvinas Holding Company LLC股票价格,Arvinas Holding Company LLC股票交易,Arvinas Holding Company LLC股票购买,Arvinas Holding Company LLC股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Arvinas Holding Company LLC(ARVN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Arvinas Holding Company LLC(ARVN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}